CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns
The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) confirmed that...
Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...
Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma
Transcenta Holding Limited (HKG: 6628) announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) has...
Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy
Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...
Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development
China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...
BMS Reports Q3 2025 Results: 2% Global Revenue Growth
US‑based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third‑quarter 2025 earnings, showing a modest 2%...
Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%
Gilead Sciences Inc. (NASDAQ: GILD) today announced its third‑quarter 2025 financial results. Total revenues reached...
MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third‑quarter 2025 financial results,...
Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B
Eli Lilly & Co. (NYSE: LLY) today announced that its third‑quarter 2025 financial results exceeded...
Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant
Jiangsu Jebel Pharma Co., Ltd. (SHA: 688566) today announced that its novel antidepressant JJH201501, developed...
Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach
Shanghai Bio‑Heart Biological Technology Co., Ltd. (HKG: 2185) announced that its subsidiary, Shanghai AngioCare Medical...
Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026
Transcenta Holding Limited (HKG: 6628) announced that its joint venture, Inhibrx Biosciences, Inc. (NASDAQ: INBX),...
HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes
HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase III clinical trials, SYMPHONY‑1 (NCT06350890)...
Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...
BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...
Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue...
JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...
Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....
Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings, Inc., a...